PATENT CLAIM ANALYSIS

Application Number: 15927255
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["530", "388100"]

Abstract:
The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.

Claim (Index 9):
The monoclonal antibody according to  claim 1 , which is a humanized or human antibody.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 90.0
- Lexical Diversity: 1.15385
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15335297', '12742546', '13701151', '10911838', '14163752']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7154867727004641
- 35 USC 102 Novelty (BERT): 0.5401660099615896
- Combined Prediction Score: 0.6979546964265766
- Mean Citation Score: 316.525802
- Max Citation Score: 390.31577
- Similarity Product: 321.55589140711663

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test